A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation.

Trial Profile

A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 May 2017 Results (n=246) assessing the effects of rituximab as a single-agent induction therapy on pre-existent or de novo DSA after renal transplantation, presented at the 2017 American Transplant Congress.
    • 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 May 2013 Interim results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top